Adult Congenital Heart Disease and Pulmonary Arterial Hypertension: The Texas Adult Congenital Heart Program Experience

References

• . Badesch DB, Champion HC, Sanchez MA, . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54( 1 suppl):S55–S66
   PubMed Web of Science ®Google Scholar
• . Galie N, Hoeper MM, Humbert M, . Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30(20):2493–2537
   PubMed Web of Science ®Google Scholar
• . McLaughlin VV, Archer SL, Badesch DB, ; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17):1573–1619
   PubMed Web of Science ®Google Scholar
• . Baumgartner H, Bonhoeffer P, De Groot NM, ; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010; 31(23):2915–2957
   PubMed Web of Science ®Google Scholar
• . Simonneau G, Robbins IM, Beghetti M, . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54( 1 suppl):S43–S54
   PubMed Web of Science ®Google Scholar
• . Lloyd-Jones D, Adams R, Carnethon M, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119(3):e21–e181
   PubMed Web of Science ®Google Scholar
• . Webb GD, Williams RG. Care of the adult with congenital heart disease: Introduction. J Am Coll Cardiol. 2001; 37(5):1166
   PubMedGoogle Scholar
• . Warnes CA, Williams RG, Bashore TM, . ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation. 2008; 118(23):e714–e833
   PubMed Web of Science ®Google Scholar
• . Webb GD. Care of adults with congenital heart disease—a challenge for the new millennium. Thorac Cardiovasc Surg. 2001; 49(1):30–34
   PubMedGoogle Scholar
• . Sommer RJ, Hijazi ZM, Rhodes JF. Pathophysiology of congenital heart disease in the adult: Part III: Complex congenital heart disease. Circulation. 2008; 117(10):1340–1350
   PubMedGoogle Scholar
• . Verheugt CL, Uiterwaal CS, van der Velde ET, . Mortality in adult congenital heart disease. Eur Heart J. 2010; 31(10):1220–1229
   PubMed Web of Science ®Google Scholar
• . Galie N, Manes A, Palazzini M, . Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs. 2008; 68(8):1049–1066
   PubMed Web of Science ®Google Scholar
• . Rhodes JF, Hijazi ZM, Sommer RJ. Pathophysiology of congenital heart disease in the adult, part II. Simple obstructive lesions. Circulation. 2008; 117(9):1228–1237
   PubMedGoogle Scholar
• . Sommer RJ, Hijazi ZM, Rhodes JF Jr. Pathophysiology of congenital heart disease in the adult: Part I: Shunt lesions. Circulation. 2008; 117(8): 1090–1099
   PubMed Web of Science ®Google Scholar
• . McLaughlin VV, Archer SL, Badesch DB, ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119(16):2250–2294
   PubMed Web of Science ®Google Scholar
• . Duffels MG, Engelfriet PM, Berger RM, . Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007; 120(2):198–204
   PubMed Web of Science ®Google Scholar
• . Bedard E, Shore DF, Gatzoulis MA. Adult congenital heart disease: A 2008 overview. Br Med Bull. 2008; 85:151–180
   PubMed Web of Science ®Google Scholar
• . Vogel M, Berger F, Kramer A, Alexi-Meshkishvili V, Lange PE. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart. 1999; 82(1):30–33
   PubMed Web of Science ®Google Scholar
• . Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53(9):733–740
   PubMed Web of Science ®Google Scholar
• . Dimopoulos K, Giannakoulas G, Wort SJ, Gatzoulis MA. Pulmonary arterial hypertension in adults with congenital heart disease: Distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol. 2008; 23(6):545–554
   PubMed Web of Science ®Google Scholar
• . Engelfriet PM, Duffels MG, Möller T, . Pulmonary arterial hypertension in adults born with a heart septal defect: The Euro Heart Survey on adult congenital heart disease. Heart. 2007; 93(6):682–687
   PubMed Web of Science ®Google Scholar
• . Verheugt CL, Uiterwaal CS, van der Velde ET, . Gender and outcome in adult congenital heart disease. Circulation. 2008; 118(1):26–32
   PubMedGoogle Scholar
• . Humbert M, Sitbon O, Chaouat A, . Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023–1030
   PubMed Web of Science ®Google Scholar
• . Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104–109
   PubMed Web of Science ®Google Scholar
• . Rowan CA, Lederer D, Lee KS, Rosenzweig EB. Ambrisentan: Safety and efficacy in the treatment of Eisenmenger syndrome. Am J Respir Crit Care Med. 2009; 179:A4919
   Google Scholar
• . Badesch DB, Raskob GE, Elliott CG, . Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest. 2010; 137(2):376–387
   PubMed Web of Science ®Google Scholar
• . Benza RL, Miller DP, Gomberg-Maitland M, . Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2): 164–172
   PubMed Web of Science ®Google Scholar
• . Humbert M, Sitbon O, Chaouat A, . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122(2):156–163
   PubMed Web of Science ®Google Scholar
• . Zannini L, Borini I. State of the art of cardiac surgery in patients with congenital heart disease. J Cardiovasc Med (Hagerstown). 2007; 8(1):3–6
   PubMedGoogle Scholar
• . Barst RJ, Foreman AJ, Ivy DD, McGoon M. REVEAL registry: Two year outcome of patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-APAH) [Abstract P1578]. Eur Heart J. 2009; 30( suppl_1):259
   Google Scholar
• . Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131(6): 1917–1928
   PubMed Web of Science ®Google Scholar
• . Galie N, Torbicki A, Barst R, ; Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004; 25(24):2243–2278
   PubMed Web of Science ®Google Scholar
• . Warnes CA. The adult with congenital heart disease: Born to be bad? J Am Coll Cardiol. 2005; 46(1):1–8
   PubMed Web of Science ®Google Scholar
• . Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: Correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011; 17(2):56–64
   PubMedGoogle Scholar
• . Safdar Z. Targeted oral therapies in the treatment of pulmonary arterial hypertension. Clin Drug Investig. 2010; 30(12):811–826
   PubMed Web of Science ®Google Scholar
• . Tuder RM, Cool CD, Geraci MW, . Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999; 159(6):1925–1932
   PubMed Web of Science ®Google Scholar
• . Safdar Z. Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respir Med. 2011; 105(6): 818–827
   PubMedGoogle Scholar
• . Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant. 2005; 24(4):501–503
   PubMed Web of Science ®Google Scholar
• . Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis. 1993; 148(2):519–522
   PubMedGoogle Scholar
• . Giaid A, Yanagisawa M, Langleben D, . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732–1739
   PubMed Web of Science ®Google Scholar
• . Hill NS, Preston IR, Roberts KE. Patients with pulmonary arterial hypertension in clinical trials: Who are they? Proc Am Thorac Soc. 2008; 5(5):603–609
   PubMedGoogle Scholar
• . Galie N, Beghetti M, Gatzoulis MA, ; Bosentan Randomized Trial of Endothelin Antagonist Threapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114(1):48–54
   PubMed Web of Science ®Google Scholar
• . Fine N, Dias B, Shoemaker G, Mehta S. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: A qualitative systematic review. Can J Cardiol. 2009; 25(3):e63–e68
   Google Scholar
• . Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005; 91(11):1447–1452
   PubMedGoogle Scholar
• . Dimopoulos K, Inuzuka R, Goletto S, . Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121(1):20–25
   PubMed Web of Science ®Google Scholar
• . Barst RJ, Gibbs JS, Ghofrani HA, . Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54( 1 suppl):S78–S84
   PubMed Web of Science ®Google Scholar
• . Galie N, Rubin L, Hoeper M, . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet. 2008; 371(9630):2093–2100
   PubMed Web of Science ®Google Scholar
• . Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004; 147(3):425–439
   PubMed Web of Science ®Google Scholar
• . Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol. 2004; 94(2):261–263
   PubMed Web of Science ®Google Scholar
• . Schulze-Neick I, Gilbert N, Ewert R, . Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy. Am Heart J. 2005; 150(4):716
   PubMedGoogle Scholar
• . Benza RL, Rayburn BK, Tallaj JA, . Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest. 2006; 129(4):1009–1015
   PubMedGoogle Scholar
• . Kourouklis S, Christopoulos A, Liagkas K, Paradellis G, Kyriakides ZS. Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension. Eur J Clin Invest. 2006; 36( suppl 3):39–43
   PubMedGoogle Scholar
• . Sitbon O, Beghetti M, Petit J, . Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest. 2006; 36( suppl 3):25–31
   PubMed Web of Science ®Google Scholar
• . Ibrahim R, Granton JT, Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can Respir J. 2006; 13(8):415–420
   PubMedGoogle Scholar
• . D'Alto M, Vizza CD, Romeo E, . Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): Safety, tolerability, clinical, and haemodynamic effect. Heart. 2007; 93(5):621–625
   PubMed Web of Science ®Google Scholar
• . Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: A 2-year study. Heart. 2007; 93(3):350–354
   PubMedGoogle Scholar
• . van Loon RL, Hoendermis ES, Duffels MG, . Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist? Am Heart J. 2007; 154(4):776–782
   PubMed Web of Science ®Google Scholar
• . Diller GP, Dimopoulos K, Kaya MG, . Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007; 93(8):974–976
   PubMed Web of Science ®Google Scholar
• . Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J. 2008; 35(3):256–261
   PubMedGoogle Scholar
• . Duffels MG, Vis JC, van Loon RL, . Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. Am J Cardiol. 2009; 103(9):1309–1315
   PubMed Web of Science ®Google Scholar
• . Lim ZS, Salmon AP, Vettukattil JJ, Veldtman GR. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol. 2007; 118(2):178–182
   PubMedGoogle Scholar
• . Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120(3):301–305
   PubMed Web of Science ®Google Scholar
• . Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationship. Int J Cardiol. 2007; 120(3):306–313
   PubMed Web of Science ®Google Scholar
• . Rimensberger PC, Spahr-Schopfer I, Berner M, . Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms. Circulation. 2001; 103(4):544–548
   PubMed Web of Science ®Google Scholar
• . Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, Soongswang J, Chanthong P, Nana A. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J Med Assoc Thai. 2005; 88( suppl 8):S60–S65
   Google Scholar
• . Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with Eisenmenger syndrome. Cardiol Rev. 2005; 13(6):312–314
   PubMedGoogle Scholar
• . Reichenberger F, Mainwood A, Doughty N, Fineberg A, Morrell NW, Pepke-Zaba J. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med. 2007; 101(2):217–222
   PubMedGoogle Scholar
• . Ivy DD, Doran AK, Smith KJ, . Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008; 51(2):161–169
   PubMed Web of Science ®Google Scholar
• . Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with longstanding pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv. 2009; 73(1):98–104
   PubMedGoogle Scholar